EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Retinoblastoma - Pipeline Review, H1 2015

  • ID: 3275720
  • Report
  • May 2015
  • 57 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • BioLineRx, Ltd.
  • Cellceutix Corporation
  • Icon Bioscience, Inc.
  • Neotropix, Inc.
  • Recombio S.L
  • MORE
Retinoblastoma - Pipeline Review, H1 2015

Summary

The‘Retinoblastoma - Pipeline Review, H1 2015’, provides an overview of the Retinoblastoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinoblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinoblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinoblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinoblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioLineRx, Ltd.
  • Cellceutix Corporation
  • Icon Bioscience, Inc.
  • Neotropix, Inc.
  • Recombio S.L
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Retinoblastoma Overview

Therapeutics Development

Pipeline Products for Retinoblastoma - Overview

Pipeline Products for Retinoblastoma - Comparative Analysis

Retinoblastoma - Therapeutics under Development by Companies

Retinoblastoma - Therapeutics under Investigation by Universities/Institutes

Retinoblastoma - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Retinoblastoma - Products under Development by Companies

Retinoblastoma - Products under Investigation by Universities/Institutes

Retinoblastoma - Companies Involved in Therapeutics Development

BioLineRx, Ltd.

Cellceutix Corporation

Icon Bioscience, Inc.

Neotropix, Inc.

Recombio S.L

RXi Pharmaceuticals Corporation

Retinoblastoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

BL-8040 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Kevetrin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

melphalan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NTX-010 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nutlin-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

racotumomab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide for Retinoblastoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Retinoblastoma - Recent Pipeline Updates

Retinoblastoma - Dormant Projects

Retinoblastoma - Product Development Milestones

Featured News & Press Releases

Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma

Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Retinoblastoma, H1 2015

Number of Products under Development for Retinoblastoma - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Products under Investigation by Universities/Institutes, H1 2015

Retinoblastoma - Pipeline by BioLineRx, Ltd., H1 2015

Retinoblastoma - Pipeline by Cellceutix Corporation, H1 2015

Retinoblastoma - Pipeline by Icon Bioscience, Inc., H1 2015

Retinoblastoma - Pipeline by Neotropix, Inc., H1 2015

Retinoblastoma - Pipeline by Recombio S.L, H1 2015

Retinoblastoma - Pipeline by RXi Pharmaceuticals Corporation, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Retinoblastoma Therapeutics - Recent Pipeline Updates, H1 2015

Retinoblastoma - Dormant Projects, H1 2015

List of Figures:

Number of Products under Development for Retinoblastoma, H1 2015

Number of Products under Development for Retinoblastoma - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Early Stage Products, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
- BioLineRx, Ltd.
- Cellceutix Corporation
- Icon Bioscience, Inc.
- Neotropix, Inc.
- Recombio S.L
- RXi Pharmaceuticals Corporation
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll